Literature DB >> 33475945

Evaluation of Optimal Post-Injection Timing of Hypoxic Imaging with 18F-Fluoromisonidazole-PET/CT.

Mitsue Kawamura1, Michio Yoshimura2, Yoichi Shimizu3, Kohei Sano3, Takayoshi Ishimori4, Yuji Nakamoto4, Takashi Mizowaki1, Masahiro Hiraoka5.   

Abstract

PURPOSE: Positron emission tomography (PET)/computed tomography (CT) using 18F-fluoromisonidazole (FMISO) has been used as an imaging tool for tumour hypoxia. However, it remains unclear whether they are useful when scanning is performed earlier, e.g. at 2-h post-injection with a high sensitivity PET scanner. This study aimed to investigate the relationship between quantitative values in 18F-fluoromisonidazole (18F-FMISO)-PET obtained at 2- and 4-h post-injection in patients with head and neck cancer. PROCEDURES: We enrolled 20 patients with untreated locally advanced head and neck cancer who underwent 18F-FMISO-PET/CT scan between August 2015 and March 2018 at our institute. Image acquisition was performed 2 h and 4 h after 18F-FMISO administration using a combined PET/CT scanner. The SUVmax, SUVmean, SUVpeak, tumour-to-blood ratio (TBR), tumour-to-muscle ratio (TMR), metabolic tumour volume (MTV), and total lesion hypoxia (TLH) were measured in the region of interest of the primary tumour. We evaluated the between-image Spearman's rank correlation coefficients and percentage differences in the quantitative values. The locations of the maximum uptake pixel were identified in both scans, and the distance between them was measured.
RESULTS: The mean (SD) SUVmax at 2 h and 4 h was 2.2(0.7) and 2.4(0.8), respectively. The Spearman's rank correlation coefficients (ρ) and mean (SD) of the percentage differences of the measures were as follows: SUVmax (0.97; 7.0 [5.1]%), SUVmean (0.97; 5.2 [5.8]%), SUVpeak (0.94; 5.3 [4.7]%), TBR (0.96; 14.2 [9.8]%), TMR (0.96; 14.7 [8.4]%), MTV (0.98; 39.9 [41.3]%), and TLH (0.98; 40.1 [43.4]%). There were significant between-scan correlations in all quantitative values. The mean (SD) distance between the two maximum uptake pixels was 7.3 (5.3) mm.
CONCLUSIONS: We observed a high correlation between the quantitative values at 2 h and 4 h. When using a combined high-quality PET/CT, the total examination time for FMISO-PET can be shortened by skipping the 4-h scan.
© 2021. World Molecular Imaging Society.

Entities:  

Keywords:  FMISO-PET; Head and neck cancer; Post-injection timing; Tumour hypoxia

Mesh:

Substances:

Year:  2021        PMID: 33475945     DOI: 10.1007/s11307-021-01580-6

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  28 in total

1.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck.

Authors:  D M Brizel; G S Sibley; L R Prosnitz; R L Scher; M W Dewhirst
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

2.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.

Authors:  L H GRAY; A D CONGER; M EBERT; S HORNSEY; O C SCOTT
Journal:  Br J Radiol       Date:  1953-12       Impact factor: 3.039

3.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.

Authors:  Marianne Nordsmark; Søren M Bentzen; Volker Rudat; David Brizel; Eric Lartigau; Peter Stadler; Axel Becker; Markus Adam; Michael Molls; Juergen Dunst; David J Terris; Jens Overgaard
Journal:  Radiother Oncol       Date:  2005-08-10       Impact factor: 6.280

4.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.

Authors:  Pierre Blanchard; Bertrand Baujat; Victoria Holostenco; Abderrahmane Bourredjem; Charlotte Baey; Jean Bourhis; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2011-06-16       Impact factor: 6.280

5.  Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?

Authors:  N Abolmaali; R Haase; A Koch; D Zips; J Steinbach; M Baumann; J Kotzerke; K Zöphel
Journal:  Nuklearmedizin       Date:  2010-12-17       Impact factor: 1.379

6.  Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.

Authors:  Joseph G Rajendran; David L Schwartz; Janet O'Sullivan; Lanell M Peterson; Patrick Ng; Jeffrey Scharnhorst; John R Grierson; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

7.  Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).

Authors:  Danny Rischin; Lester Peters; Richard Fisher; Andrew Macann; Jim Denham; Michael Poulsen; Michael Jackson; Lizbeth Kenny; Michael Penniment; June Corry; David Lamb; Bev McClure
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

8.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

9.  High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.

Authors:  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Yoichi M Ito; Keiichi Magota; Katsuhiko Kasai; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

10.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.

Authors:  W J Koh; K S Bergman; J S Rasey; L M Peterson; M L Evans; M M Graham; J R Grierson; K L Lindsley; T K Lewellen; K A Krohn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-09-30       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.